Closure of Takeda California San Francisco Site and Relocation of Takeda Antibody and Biologics Research to San Diego

Closure of Takeda California San Francisco Site and Relocation of Takeda Antibody and Biologics Research to San Diego

San Diego, California, May 18, 2012 – Takeda California, Inc. (Takeda California), announced today a restructuring of the company, including closing its San Francisco site and relocating the most essential antibody and biologics research technologies and staff to San Diego.

The action follows the legal merger of Takeda San Diego and Takeda San Francisco, to form Takeda California on January 1 2012, and the reorganization enables the company to enhance communication and collaboration, and to capture synergies by co-localizing its staff, management, and research operations into a single site in San Diego. After the restructure, Takeda California will have the unique capability within Takeda research to address unmet medical needs in cancer, immunology, and metabolic disease by antibody biologics and small molecule approaches, and combinations thereof.

"This decision supports our continuous efforts to enhance the efficiency and effectiveness of Takeda's global research activities," said Paul Chapman, Senior Vice President of Takeda's Pharmaceutical Research Division. "Takeda California, with its broad and flexible drug discovery capabilities, is an important asset and contributor to Takeda's productivity."

Takeda California is Takeda's center of excellence and innovation for structure-based drug discovery and protein therapeutics. The company combines cutting-edge protein X-ray crystallography, small molecule, antibody, and antibody drug-conjugate capabilities to efficiently generate potential new medicines for treating cancer, inflammatory diseases and metabolic diseases. Multiple potential new drugs invented at Takeda California are in clinical trials evaluation including NESINA® (generic name Alogliptin) which was approved in Japan, in 2010, for treating patients with type II diabetes.

Takeda California is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company and one with a 230-year heritage. Together with its worldwide partners in science, Takeda California is committed to strive toward better health for patients through leading innovation in medicine.

To learn more about Takeda's global operations, please visit http://www.takeda.com.

For all press enquiries please contact:

Kortney D. Oliver
Director
Olive PR Solutions
(415) 866-7040
[email protected]

Suggested Articles

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera

Tranquis Therapeutics launched with $30 million to create a new class of medicines for illnesses like amyotrophic lateral sclerosis and Alzheimer’s.

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.